Skip to content
NewsBlazeAU – Lifestyle
Author:
argenx SE
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 27, 2026
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
July 23, 2026
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
July 16, 2026
argenx to Host Autoimmune Myositis R&D Webinar
June 23, 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
June 3, 2026
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026
argenx to Present at Upcoming Investor Conferences
May 27, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 8, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026
1
2
Next Page
→